comparemela.com

Latest Breaking News On - James vane tempest - Page 5 : comparemela.com

Fresenius Shares Rise After Better-Than-Expected Results

SCHOTT PHARMA : Jefferies gives a Neutral rating -February 13, 2024 at 08:28 am EST

In his latest research note, analyst James Vane-Tempest confirms his recommendation. The broker Jefferies is keeping its Neutral rating. The target price is unchanged and still at EUR 34.30.

GERRESHEIMER AG : Jefferies reiterates its Buy rating -February 08, 2024 at 09:42 am EST

In his latest research note, analyst James Vane-Tempest confirms his positive recommendation. The broker Jefferies is keeping its Buy rating. The target price is still set at EUR 120.

FRESENIUS SE : Jefferies maintains a Buy rating -February 02, 2024 at 05:16 am EST

James Vane-Tempest from Jefferies retains his positive opinion on the stock with a Buy rating. The target price remains set at EUR 41.

SARTORIUS VORZUEGE : Jefferies remains Neutral -February 02, 2024 at 10:33 am EST

Initially Neutral on the company, Jefferies s analyst James Vane-Tempest maintained his recommendation. The target price is increased from EUR 264 to EUR 313.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.